Edinburgh UK, 11th November 2022 - Kynos Therapeutics Ltd, an immune-metabolic company with world-leading expertise in the kynurenine pathway and kynurenine 3-monooxygenase (KMO) biology, today announced the appointment Dr Jonathan Savidge as CEO. The appointment is part of the next stage in the development of the company as it moves novel KMO inhibitors into clinical development. Jonathan brings a wealth of experience in fundraising and business and corporate development, having previously been founding CEO of Syndesi Therapeutics and concluding an acquisition deal earlier this year with a headline value of $1BN.
Jonathan joins the Kynos Therapeutics leadership team comprising the founders, Professors Damian Mole and Scott Webster and CFO Alison Strutt. Professor Mole, founding CEO, will continue to play a key role in the company as scientific expert and champion, assuming the title of Chief Scientific Officer. Professor Webster will continue to oversee the development of molecules into the clinic as Chief Technology Officer.
Commenting on his appointment as CEO, Jonathan Savidge said “I am thrilled to join the team at Kynos at this exciting time as the company prepares to move into clinical development. The Kynos founders have built a world-leading expertise in the KMO target with a lead molecule poised to enter the clinic. I look forward to working with them, the rest of the Kynos team and the Board to progress development of these innovative KMO inhibitors and evolve the company to its next stage.”
Kynos Therapeutics founder and CSO Damian Mole said “I am delighted to welcome Jonathan to the company. His track record and complementary skill set significantly strengthens the existing Kynos leadership team and will accelerate the development of the company and its KMO platform.”
About Kynos Therapeutics
Kynos Therapeutics is developing an innovative pipeline of first-in-class kynurenine 3-monooxygenase (KMO) inhibitors. KMO plays a major role in the regulation of inflammation, acting at the interface between inflammation, immunity and metabolism, and inhibition of KMO has therapeutic potential in a range of indications. Spun out from the University of Edinburgh, Kynos leverages a decade of drug discovery research on KMO inhibitors originally co-developed through a collaboration between GSK and the University of Edinburgh and now exclusively licensed to Kynos. Based in Edinburgh, UK, the company is backed by founding investor Epidarex Capital as well as IP Group plc and Scottish Enterprise with additional non-dilutive funding from Innovate UK.